HomeCompareCAIHF vs JNJ

CAIHF vs JNJ: Dividend Comparison 2026

CAIHF yields 714.29% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CAIHF wins by $1074071.48M in total portfolio value
10 years
CAIHF
CAIHF
● Live price
714.29%
Share price
$0.28
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1074071.51M
Annual income
$842,144,038,884.19
Full CAIHF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — CAIHF vs JNJ

📍 CAIHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCAIHFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CAIHF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CAIHF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CAIHF
Annual income on $10K today (after 15% tax)
$60,714.29/yr
After 10yr DRIP, annual income (after tax)
$715,822,433,051.56/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, CAIHF beats the other by $715,822,429,065.57/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CAIHF + JNJ for your $10,000?

CAIHF: 50%JNJ: 50%
100% JNJ50/50100% CAIHF
Portfolio after 10yr
$537035.77M
Annual income
$421,072,021,786.79/yr
Blended yield
78.41%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

CAIHF
No analyst data
Altman Z
2.5
Piotroski
7/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CAIHF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCAIHFJNJ
Forward yield714.29%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$1074071.51M$30.3K
Annual income after 10y$842,144,038,884.19$4,689.40
Total dividends collected$1055362.50M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CAIHF vs JNJ ($10,000, DRIP)

YearCAIHF PortfolioCAIHF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$82,129$71,428.57$10,592$272.30+$71.5KCAIHF
2$636,132$548,254.82$11,289$357.73+$624.8KCAIHF
3$4,649,395$3,968,733.31$12,123$472.89+$4.64MCAIHF
4$32,084,076$27,109,223.13$13,141$629.86+$32.07MCAIHF
5$209,164,159$174,834,198.35$14,408$846.81+$209.15MCAIHF
6$1,289,028,186$1,065,222,534.95$16,021$1,151.60+$1289.01MCAIHF
7$7,514,502,356$6,135,242,197.78$18,122$1,588.22+$7514.48MCAIHF
8$41,466,620,398$33,426,102,876.85$20,930$2,228.20+$41466.60MCAIHF
9$216,754,645,306$172,385,361,480.07$24,792$3,191.91+$216754.62MCAIHF
10$1,074,071,509,362$842,144,038,884.19$30,274$4,689.40+$1074071.48MCAIHF

CAIHF vs JNJ: Complete Analysis 2026

CAIHFStock

Chia Tai Enterprises International Limited engages in the manufacture and sale of chlortetracycline (CTC) and other related products in Mainland China, the Asia Pacific, the Americas, Europe, and internationally. It operates through two segments, Biochemical and Industrial. The Biochemical segment manufactures and sells CTC premix and CTC hydrochloride products, which are used as feed additives to promote growth of livestock, prevent or cure animal diseases, and enhance feed efficiency under the Shihao and Citifac brands. The Industrial segment engages in the sale, leasing, and servicing of caterpillar machinery equipment, including excavators, power generators, bulldozers, and compactors, as well as spare parts; and manufacture and sale of carburetors and automotive parts for automobile and motorcycle manufacturers. The company was incorporated in 1987 and is based in Central, Hong Kong. Chia Tai Enterprises International Limited is a subsidiary of Charoen Pokphand Foods Public Company Limited.

Full CAIHF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this CAIHF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CAIHF vs SCHDCAIHF vs JEPICAIHF vs OCAIHF vs KOCAIHF vs MAINCAIHF vs ABBVCAIHF vs MRKCAIHF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.